Skip to main content

Advertisement

Table 1 Baseline characteristics of patients

From: A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis

  Total Patients starting with animated exercise program (Wii console)a1 Patients starting with conventional home-based physical exercisesa1
Number of patients, n 30 15 15
Age (years), mean (SD) 56 (±9) 52 (±8) 59 (±9)
Age (years), min. 34 34 45
Age (years), max. 69 65 69
Age > 60 years, n (%) 11 (37 %) 3 (20 %) 8 (53 %)
Age 50 – 60 years, n (%) 10 (33 %) 7 (47 %) 3 (20 %)
Age <50 years, n (%) 9 (30 %) 5 (33 %) 4 (27 %)
Female, n (%) 25 (83 %) 10 (67 %) 15 (100 %)
Disease duration (years), mean (SD) 13 (±9) 10 (±7) 16 (±9)
disease duration (years), max. 36 26 36
disease duration (years), min. 1 1 1
DAS28, mean (SD) 2.8 (±1.2) 3.0 (±1.5) 2.6 (±0.9)
DAS28 score, max. 5.3 5.3 4.4
DAS28 score, min. 0.5 0.9 0.5
HAQ-DI score, mean (SD) 0.85 (±0.53) 0.72 (±0.52) 0.98 (±0.51)
HAQ-DI score, max. 1.75 1.75 1.63
HAQ-DI score, min. 0.00 0.00 0.00
Patient’s VAS disease activity, mm 17 16 18
Current biological DMARD therapy
 Rituximab, n (%) 12 (40 %) 7 (47 %) 5 (33 %)
 Tocilizumab, n (%) 10 (33 %) 5 (33 %) 5 (33 %)
 Abatacept, n (%) 5 (17 %) 2 (13 %) 3 (20 %)
 Etanercept, n (%) 2 (6 %) 1 (7 %) 1 (7 %)
 Certolizumab, n (%) 1 (3 %) 0 (0 %) 1 (7 %)
Previous biological DMARD therapy
 Rituximab, n (%) 4 (13 %) 2 (13 %) 2 (13 %)
 Tocilizumab, n (%) 3 (10 %) 1 (7 %) 2 (13 %)
 Abatacept, n (%) 2 (6 %) 1 (7 %) 1 (7 %)
 Etanercept, n (%) 10 (33 %) 7 (47 %) 3 (20 %)
 Certolizumab, n (%) 1 (3 %) 1 (7 %) 0 (0 %)
 Golimumab, n (%) 1 (3 %) 0 (0 %) 1 (7 %)
 Secukinumab, n (%) 1 (3 %) 1 (7 %) 0 (0 %)
 Infliximab, n (%) 6 (20 %) 2 (13 %) 4 (27 %)
 Anakinra, n (%) 1 (3 %) 1 (7 %) 0 (0 %)
  ≥ 3 previous biological DMARD’s, n 7 (23 %) 4 (27 %) 3 (20 %)
  ≥ 2 previous biological DMARD’s, n 8 (27 %) 4 (27 %) 4 (27 %)
 only 1 previous biological DMARD, n 6 (20 %) 2 (13 %) 4 (27 %)
  1. a1 with a cross-over to the other treatment arm after 12 weeks SD, standard deviation; min, minimum; max, maximum; HAQ-DI, health assessment questionnaire disability index; DAS28, disease activity score using the 28 joint count; DMARD, disease modifying anti-rheumatic drug; VAS, Visual analogue scale